// App-Quantinova.ai

P3-07-03 : GPNMB activates EGFR to overcome Mek-inhibition: Implications for the development of rational targeted therapy combinations in triple negative breast cancer

Researchers

Presenter

  • A Rose

Principal Investigators

  • M Annis

  • D Perkins

  • P Siegel

Medical Centers

  • McGill University, Department of Oncology, Montreal, QC, Canada

  • Goodman Cancer Research Centre, Montreal, QC, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

  • Breast cancer

  • Melanoma

  • Solid malignancies

Biomarkers

  • Mitogen-activated protein kinase

  • Epidermal growth factor receptor

  • Human epidermal growth factor receptor 2

  • Transcription Factor Binding To IGHM Enhancer 3

Drug/Treatment

  • Cobimetinib

  • Trametinib

  • CDX-011

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved